Evolution of bone marrow transplantation--the original immunotherapy.
Allogeneic bone-marrow transplantation (BMT) has provided a curative treatment option for chronic myeloid leukaemia (CML) over the past 20-30 years. New drugs - signal transduction inhibitors - that target the bcr-abl oncogene have the potential to render such transplantation procedures obsolete and provide hope for those without a suitable donor ( approximately 60% of patients). Here, we discuss how new drug and immune-based approaches could be combined to enhance treatment of this already 'curable' malignancy.
Campbell
J D
JD
Academic Transfusion Medicine Unit (ATMU), Dept of Medicine, Royal Infirmary, 10 Alexandra Parade, G31 2ER., Glasgow, UK.
Cook
G
G
Holyoake
T L
TL
D016026:Bone Marrow Transplantation / Q000379:methods* / Q000639:trends*; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000628:therapy